脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响

付华; 周国超; 蔡融民; 宋新; 杨定华

doi:10.19401/j.cnki.1007-3639.2025.05.002

您当前的位置：

首页 >

文章列表页 >

脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响

论著 | 更新时间：2025-12-31

- 脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响
- Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3
- 中国癌症杂志 2025年35卷第5期页码：440-448
- 作者机构：
  
  湘西自治州人民医院肝胆一科，湖南湘西 416000
- 作者简介：
  
  [ "付华（ORCID: 0009-0002-0035-5074），学士，主治医师。" ]
  周国超（ORCID: 0000-0002-1692-2179），硕士研究生，副主任医师。
- 基金信息：
  
  湖南省卫生健康委科研计划项目(202204014693)
- DOI：10.19401/j.cnki.1007-3639.2025.05.002
  中图分类号： R735.9
- 收稿：2024-12-19，
  
  修回：2025-04-01，
  
  纸质出版：2025-05-30
- 稿件说明：
移动端阅览
付华, 周国超, 蔡融民, 等. 脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响[J]. 中国癌症杂志, 2025,35(5):440-448.

Hua FU, Guochao ZHOU, Rongmin CAI, et al. Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3[J]. China Oncology, 2025, 35(5): 440-448.
付华, 周国超, 蔡融民, 等. 脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响[J]. 中国癌症杂志, 2025,35(5):440-448. DOI： 10.19401/j.cnki.1007-3639.2025.05.002.

Hua FU, Guochao ZHOU, Rongmin CAI, et al. Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3[J]. China Oncology, 2025, 35(5): 440-448. DOI： 10.19401/j.cnki.1007-3639.2025.05.002.

摘要

背景与目的：

胰腺癌对白蛋白结合型紫杉醇耐药会影响疗效及患者预后，信号转导及转录激活因子3（signal transducer and activator of transcription 3，STAT3）是调控癌细胞化疗敏感性的重要分子之一，针对STAT3 mRNA反义寡核苷酸的中性脂质体BP1003能够抑制STAT3表达并

增加化疗敏感性。但BP1003对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响尚不清楚。本研究旨在研究脂质体结合的反义寡核苷酸BP1003通过抑制STAT3对胰腺癌细胞白蛋白结合型紫杉醇敏感性的影响。

方法：

培养胰腺癌细胞株PANC-1及ASPC-1，分为对照组（不含药物）、BP1003组（200 μg/mL BP1003干预）、不同浓度白蛋白结合型紫杉醇组（5、10、20 nmol/L白蛋白结合型紫杉醇干预）、BP1003+不同浓度白蛋白结合型紫杉醇组（200 μg/mL BP1003联合5、10、20 nmol/L白蛋白结合型紫杉醇干预）。检测细胞增殖活力、凋亡率及STAT3、STAT4、STAT6、Bcl-2、Bax、c-Myc的蛋白表达水平。BALC/c裸小鼠皮下注射PANC-1、ASPC-1细胞悬液，建立移植瘤模型，分为对照组（生理盐水干预）、BP1003组（25 mg/kg BP1003干预，每2周1次）、白蛋白结合型紫杉醇组（10 mg/kg白蛋白结合型紫杉醇，每周1次）、BP1003+白蛋白结合型紫杉醇组（25 mg/kg BP1003干预，每2周1次联合10 mg/kg白蛋白结合型紫杉醇，每周1次）。4周后测量移植瘤体积及质量，检测STAT3、Bcl-2、Bax、c-Myc的蛋白表达水平。

结果：

BP1003组及不同浓度白蛋白结合型紫杉醇组PANC-1及ASPC-1细胞的凋亡率、Bax的蛋白表达水平均高于对照组，细胞增殖活力及STAT3、Bcl-2、c-Myc的蛋白表达水平低于对照组（

0.05）。BP1003组PANC-1及ASPC-1细胞的STAT4、STAT6蛋白表达水平与对照组相比差异无统计学意义（

0.05）。BP1003+不同浓度白蛋白结合型紫杉醇组PANC-1及ASPC-1细胞的凋亡率、Bax的蛋白表达水平均高于对应浓度白蛋白结合型紫杉醇组，细胞增殖活力及STAT3、Bcl-2、c-Myc的蛋白表达水平均低于对应浓度白蛋白结合型紫杉醇组（

0.05）。BP1003组、白蛋白结合型紫杉醇组、BP1003+白蛋白结合型紫杉醇组裸鼠移植瘤的体积、质量及STAT3、Bcl-2、c-Myc的蛋白表达水平均低于对照组，Bax的蛋白表达水平高于对照组（

0.05）且BP1003+白蛋白结合型紫杉醇组的上述变化较BP1003组、白蛋白结合型紫杉醇组更为显著。

结论：

BP1003通过抑制STAT3表达增加胰腺癌细胞对白蛋白结合型紫杉醇的敏感性。

Abstract

Background and purpose:

The resistance of pancreatic cancer to albumin-bound paclitaxel affects the therapeutic effect and prognosis. Signal transducer and activator of transcription 3 (STAT3) is one of the important molecules regulating the chemotherapy sensitivity of cancer cells. The liposome BP1003 targeting the antisense oligonucleotide of STAT3 mRNA can inhibit the expression of STAT3 and increase the chemotherapy sensitivity. However

the effect of BP1003 on the sensitivity of pancreatic cancer cells to albumin-bound paclitaxel remains unclear. The purpose of this study was to investigate the effects of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3.

Methods:

Pancreatic cancer cell lines PANC-1 and ASPC-1 were cultured. They were divided into control group (without drugs)

BP1003 group (200 μg/mL BP1003 intervention)

different concentrations of albumin-bound paclitaxel group (5

20 nmol/L albumin-bound paclitaxel intervention)

BP1003+different concentrations of albumin-bound paclitaxel group (200 μg/mL BP1003 combined with 5

20 nmol/L albumin-bound paclitaxel intervention). The proliferation viability

apoptotic rate and the protein expression levels of STAT3

STAT4

STAT6

Bcl-2

Bax and c-Myc were detected. The transplanted tumor model was established by subcutaneous injection of PANC-1 and ASPC-1 cell suspension in nude mice

which were divided into control group (normal saline intervention)

BP1003 group (25 mg/kg BP1003 intervention

once every 2 weeks) and albumin-bound paclitaxel group (10 mg/kg albumin-bound paclitaxel

once a week)

BP1003+albumin-bound paclitaxel group (25 mg/kg BP1003 intervention

once every 2 weeks combined with 10 mg/kg albumin-bound paclitaxel

once a week). Four weeks later

the graft volume and mass were measured

and the protein expression levels of STAT3

Bcl-2

Bax and c-Myc were detected.

Results:

The apoptotic rate and the protein expression levels of Bax of PANC-1 and ASPC-1 cells in BP1003 group and albumin-bound paclitaxel group were higher than those in the control group

while the proliferation viability and protein expression levels of STAT3

Bcl-2 and c-Myc were lower than those in control group (

0.05). There was no significant difference in the expression levels of STAT4 and STAT6 in PANC-1 and ASPC-1 cells between BP1003 group and the control group (

0.05). The apoptotic rate and the protein expression levels of Bax of PANC-1 and ASPC-1 cells in BP1003+different concentrations of albumin-bound paclitaxel groups were higher than those in different concentrations of albumin-bound paclitaxel groups

and the proliferation viability and protein expression lev

els of STAT3

Bcl-2 and c-Myc were lower than those in different concentrations of albumin-bound paclitaxel groups (

0.05). The volume and mass of transplanted tumor and the protein expression levels of STAT3

Bcl-2 and c-Myc of nude mice in BP1003 group

albumin-bound paclitaxel group and BP1003+albumin-bound paclitaxel group were all lower compared with the control group

the protein expression level of Bax was higher compared with the control group (

0.05)

and the above changes in BP1003+albumin-bound paclitaxel group were more significant compared with BP1003 and albumin-bound paclitaxel group.

Conclusion:

BP1003 increases the sensitivity of pancreatic cancer cells to albumin-bound paclitaxel by inhibiting the expression of STAT3.

关键词

Keywords

references

HUANG J J , LOK V , NGAI C H , et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer [J ] . Gastroenterology , 2021 , 160 ( 3 ): 744 - 754 . DOI: 10.1053/j.gastro.2020.10.007 http://doi.org/10.1053/j.gastro.2020.10.007

刘永鹏 , 张晶晶 , 任艳 , 等 . 1990—2019年中国胰腺癌疾病负担变化趋势研究 [J ] . 现代预防医学 , 2022 , 49 ( 17 ): 3079 - 3085 .

LIU Y P , ZHANG J J , REN Y , et al. Trends of disease burden of pancreatic cancer in China, 1990: 2019 [J ] . Mod Prev Med , 2022, 49 ( 17 ): 3079 - 3085 .

BODEKER K L , SMITH B J , BERG D J , et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer [J ] . Redox Biol , 2024 , 77 : 103375 .

JIN M , LIU H L , XUE J , et al. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study [J ] . Oncologist , 2024 , 29 ( 10 ): e1406-e1418.

BLASZCZAK W , WHITE B , MONTERISI S , et al. Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells [J ] . Cell Rep , 2024 , 43 ( 1 ): 113612.

DING L Y , WANG Q W , MARTINCUKS A , et al. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer [J ] . J Immunother Cancer , 2023 , 11 ( 1 ): e005627.

ZHU Z Y , XIANG Q , LI S Q , et al. Serine/threonine kinase 16 phosphorylates STAT3 and confers a JAK2-inhibition resistance phenotype in triple-negative breast cancer [J ] . Biochem Pharmacol , 2024 , 225 : 116268 .

GAGLIARDI M , KEAN R , DAI B B , et al. BP1003 decreases STAT3 expression and its pro-tumorigenic functions in solid tumors and the tumor microenvironment [J ] . Biomedicines , 2024 , 12 ( 8 ): 1901.

李静 , 王志芬 , 张晓慧 , 等 . 阿帕替尼与白蛋白结合型紫杉醇在MDA-MB-231乳腺癌细胞系中的协同抗癌作用 [J ] . 中华细胞与干细胞杂志(电子版) , 2021 , 11 ( 2 ): 90 - 98 .

LI J , WANG Z F , ZHANG X H , et al. Synergistic anticancer effects of apatinib and nab-paclitaxel in MDA-MB-231 breast cancer cell line [J ] . Chin J Cell Stem Cell Electron Ed , 2021 , 11 ( 2 ): 90 - 98 .

AL-HETTY H R A K , ABDULAMEER S J , ALKUBAISY S A , et al. STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target [J ] . Pathol Res Pract , 2023 , 245 : 154425 .

CHEN H , BIAN A W , YANG L F , et al. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression [J ] . Oncogene , 2021 , 40 ( 8 ): 1440 - 1457 . DOI: 10.1038/s41388-020-01626-z http://doi.org/10.1038/s41388-020-01626-z

CHEN H , ZHOU W B , BIAN A W , et al. Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer [J ] . Clin Cancer Res , 2023 , 29 ( 4 ): 815 - 830 .

GUO H C , XIAO Y Y , YUAN Z W , et al. Inhibition of STAT3Y705 phosphorylation by stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells [J ] . Cell Death Discov , 2022 , 8 ( 1 ): 116.

HE Y , HAN P Y , CHEN C , et al. circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation [J ] . Cancer Gene Ther , 2023 , 30 ( 4 ): 559 - 566 .

HE Z W , WANG J , ZHU C H , et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis [J ] . Cancer Lett , 2022 , 548 : 215751 .

LIU H N , PAN D , YAO Z Y , et al. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer [J ] . Int Immunopharmacol , 2024 , 139 : 112635 .

GIORDANO G , MILELLA M , LANDRISCINA M , et al. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment [J ] . Cancer Med , 2024 , 13 ( 12 ): e7345.

AGOSTINI A , GUERRIERO I , PIRO G , et al. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer [J ] . J Transl Med , 2023 , 21 ( 1 ): 843.

UDDIN M H , AL-HALLAK M N , KHAN H Y , et al. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model [J ] . Clin Transl Med , 2023 , 13 ( 12 ): e1513.

VOISIN T , NICOLE P , GRATIO V , et al. The orexin-A/OX1R system induces cell death in pancreatic cancer cells resistant to gemcitabine and nab-paclitaxel treatment [J ] . Front Oncol , 2022 , 12 : 904327 .

OUYANG S M , LI H X , LOU L L , et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer [J ] . Redox Biol , 2022 , 52 : 102317 .

SADRKHANLOO M , PASKEH M D A , HASHEMI M , et al. STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions [J ] . Biomed Pharmacother , 2023 , 158 : 114168 .

SINGH S , GOMEZ H J , THAKKAR S , et al. Overcoming acquired drug resistance to cancer therapies through targeted STAT3 inhibition [J ] . Int J Mol Sci , 2023 , 24 ( 5 ): 4722.

HSIEH Y C , DAI Y C , CHENG K T , et al. Blockade of the SRC/STAT3/BCL-2 signaling axis sustains the cytotoxicity in human colorectal cancer cell lines induced by dehydroxyhispolon methyl ether [J ] . Biomedicines , 2023 , 11 ( 9 ): 2530.

LIU J S , YEH C A , HUANG I C , et al. Signal transducer and activator of transcription 3 mediates apoptosis inhibition through reducing mitochondrial ROS and activating Bcl-2 in gemcitabine-resistant lung cancer A549 cells [J ] . J Cell Physiol , 2021 , 236 ( 5 ): 3896 - 3905 .

XIANG X X , YUAN D , LIU Y , et al. PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression [J ] . Acta Biochim Biophys Sin (Shanghai) , 2018 , 50 ( 8 ): 800 - 806 .

YU S , GONG L S , LI N F , et al. Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways [J ] . Biomed Pharmacother , 2018 , 97 : 213 - 224 . DOI: S0753-3322(17)32622-7 http://doi.org/S0753-3322(17)32622-7

浏览量

850

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

FBW7基因通过GSDME介导的焦亡增强紫杉醇对胰腺癌的抗肿瘤作用研究

SERPINA3通过抑制铁死亡促进胰腺癌的恶性进展及吉西他滨耐药的机制研究

2024年胰腺癌研究及诊疗新进展

胰腺癌吉西他滨化疗耐药生物标志物—INPP4B的探索性研究

uPAR通过MAPK信号抑制细胞自噬促进胰腺癌增殖、侵袭及化疗抵抗的作用研究